ADDIEVI AMPER: Open Payments
NPI 1346671401 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 5 payments from 5 companies in 2025. Trend: 2023 $381 · 2024 $974 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| Melinta Therapeutics, LLC | 1 | $125 |
| Alkermes, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $88 |
Products named: Rezzayo, ARISTADA, CAPLYTA, REXULTI.
Industry payments across TX — which companies pay providers there.
